Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board
2 Polyphor to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Treatment of HER
3 Kidney Cancer PDOXs Reveal Patient‐specific Pro‐malignant Effects of Antiangiogenics and Its Molecular Traits
4 Hormone Receptor, pCR May Point to Survival on Dual HER2 Blockade
5 Movers & Shakers, Nov. 20 | BioSpace
6 Pathologic Complete Response to Targeted Therapy Before Surgery Linked to Better Survival for Early-Stage HER2-Positive Breast Cancer
7 Antiangiogenic therapy can cause malignancy in kidney cancers
8 BRCA1/2 and Beyond
9 Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
10 PARPi olaparib for the targeted treatment of metastatic prostate cancer
11 Antiangiogenic drugs increase the aggressiveness of some kidney tumors
12 COVID-19 lesson from Spain: Like the US, we failed to take this seriously before it came to us—we have to learn
13 Novel agent reactivates an immune call by LIF blockade
14 European Cancer Centers Restructure Care in the Era of COVID-19
15 Study Finds Patients with HER2+ Breast Cancer Live Longer if Anti-Cancer Drugs Induce pCR
16 Olaparib Significantly Improves OS in mCRPC Subgroup
17 Tabernero Finds New Paths in Gastrointestinal Treatment Landscape
18 Countless Options to Improve Future Outcomes in Subgroups of Patients With GU Cancers
19 Novel Tx Helps Some Advanced Cervical Cancer Patients
20 Novel biomarkers predict benefit with immunotherapy in metastatic breast cancer
21 Dostarlimab Shows Promising Antitumor Activity in Mismatch Repair Deficient, Proficient Endometrial Cancer
22 HER2+ breast cancer patients live longer if drugs given before surgery eradicate tumour
23 Pembrolizumab appears promising for certain patients with gastric, gastroesophageal cancer
24 Dostarlimab Shows Promise for Advanced Endometrial Cancer, Early...
25 IcanoMAB GmbH Founded with Private Funding to Develop Precision Canonical Monoclonal Antibodies in Oncology, Immune-Modulation, Acute Inflammation and Most Urgently for Covid-19
26 ESMO Releases Recommendations on Next-Generation Sequencing for Metastatic Cancers
27 Dr. Oaknin on the Safety Profile of Dostarlimab in Endometrial Cancer
28 ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advance...
29 Immunoscore included in ESMO Clinical Practice Guidelines 2020
30 Not All Prostate Cancer Mutations Created Equal for Olaparib
31 New first-line treatment option for metastatic kidney cancer
32 Ripretinib Shows Survival Benefit in Patients With GIST Who Crossed Over After Progression in Phase 3 Study
33 Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
34 Durvalumab/Tremelimumab Shows Modest Activity in Advanced NETs With GEP and Lung Origins
35 Novel BTK Inhibitor Appears Promising in Mantle Cell Lymphoma and Other NHLs
36 Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abi...
37 Encorafenib Plus Cetuximab Approved in Europe for BRAF V600E-Mutant mCRC
38 Dr. Roué on the Synergistic Activity With TG-1701, Ublituximab, and Umbralisib in MCL
39 NeoPhore Strengthens Scientific Leadership Team
40 New Data Show Response for Subset of Endometrial Cancer Patients Treated With GSK's Dostarlimab
41 ESMO issues first recommendations on using next-generation sequencing for advanced cancers
42 GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
43 Unique tool paves the way for more individualized cancer treatments
44 pCR Put Forth as a Surrogate Marker for Improved Survival in Early HER2+ Breast Cancer
45 Encorafenib Now Approved for BRAF-Positive Colorectal Cancer
46 Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
47 More options to combat stomach cancer
48 The co-occurrence of cancer driver genes, key to precision medicine
49 Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis | DNA RNA and Cells | News Channels
50 Pierre Fabre Receives European Approval for BRAFTOVI® (encorafenib) in Combination With Cetuximab for the Treatment of Adult Patients With BRAFV600E-Mutant Metastatic Colorectal Cancer
51 Integrating PARP inhibitors into the Standard of Care for Prostate Cancer
52 New hydrogels for T-cell growth to be used in cancer immunotherapy
53 Spanish Startup Aims to Develop Novel Genomic Tests to Guide Breast Cancer Treatment
54 Frontline Pembrolizumab Plus Chemo Shows Compelling PFS Improvement in PD-L1+ TNBC
55 EC approves added indication for Braftovi in mCRC
56 Dr. Oaknin on the GARNET Study in Endometrial Cancer
57 Pioneering cell therapies for non-responders to current immunotherapies
58 Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain
59 Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer
60 Advances in Cancer Drug Discovery
61 PARP Inhibitors Move Into First-Line for Ovarian Cancer
62 Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium
63 Cancer Is Not Going Away During COVID-19: Physician-in-Chief Lisa DeAngelis Shares Why Patients Need to Get Back to the Clinic
64 GSK's dostarlimab shows promise in endometrial cancer
65 Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)
66 COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
67 Novel treatment combination for patients with BRAF-mutant metastatic colorectal cancer
68 Immutep : ESMO 2020
69 Genetic gene mutations: Opening new therapeutic avenues in metastatic prostate cancer
70 Asco 2020 – Keytruda a “new standard” in biomarker-driven cancer
71 Regorafenib dosing strategies reduce adverse events among patients with colorectal cancer
72 Refining Adjuvant Treatment Options for Colorectal Cancer
73 Analysis of Patients With Prior Gastrectomy Treated With LONSURF® (trifluridine/tipiracil) Published in JAMA Oncology
74 Lurbinectedin for BRCA-mutated advanced breast cancer
75 AI Combining Radiomics, Clinical Data Predicts Response to Immunotherapy
76 Immunotherapy in combination points to paradigm shift in the treatment of cervical cancer
77 Global Antibody Discovery Services and Platforms Market 2020-2030: Analysis of Antibody Discovery Technologies and Services that Assist in the Development of Antibody Therapeutics
78 WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology
79 Pembro Noninferior, Less Toxic Than Chemo in Gastric Cancer
80 11 institutions join AACR Project GENIE Consortium
81 Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients
82 Precision Medicine: A New Frontier for Advanced Cholangiocarcinoma
83 Netherlands Drug Repurposing, Tumor Profiling Trial Results Reported at ESMO
84 A response key for survival of Mycoplasma genitalium in the urogenital tract uncovered
85 New ESMO Scale Aims to Bring Order to Mutation Analysis
86 Outlook on the Global Bispecific Antibody Therapeutics Market (2019 to 2030)
87 LONSURF® (trifluridine/tipiracil) Receives Marketing Authorization in Europe for Patients With Previously Treated Metastatic Gastric Cancer
88 Living with advanced breast cancer
89 SUO 2019: Poly ADP Ribose Polymerase (PARP) Inhibitors for Prostate Cancer
90 ESMO 2019: Promising Development in Treatment of Colorectal and Pancreatic Cancer
91 A Step Forward for Targeted Agents in Advanced NETs?
92 Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Re | CEOR
93 Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.
94 Lonsurf receives positive CHMP opinion
95 Performance of Comprehensive Risk Adjustment for the Prediction of In- | RMHP
96 Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancer
97 Emerging Concepts in HER2-Driven GI Cancers
98 European Medicines Agency Grants PRIME Access to ADP-A2M4 for Synovial Sarcoma
99 BEACON Trial in BRAF-Mutant mCRC: Now Published, Criticized
100 Gastric Cancer Incidence Increasing in Younger Population in Latin America